^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ovarian Cancer
    Drug:ofranergene obadenovec (VB-111) (Angiogenesis inhibitor, Vascular disrupting agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    VBL Therapeutics Press Release
    Title:

    VBL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR OFRA-VEC FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER

    Published date:
    04/26/2022
    Excerpt:
    VBL Therapeutic...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.
    Secondary therapy:
    bisphosphonate bound paclitaxel